Cytotoxicity of Thiopurine Drugs in Patients with Inflammatory Bowel Disease

被引：13

作者：

Zakerska-Banaszak, Oliwia ^{[1
]}

Lykowska-Szuber, Liliana ^{[2
]}

Walczak, Michal ^{[1
]}

Zuraszek, Joanna ^{[1
]}

Zielinska, Aleksandra ^{[1
]}

Skrzypczak-Zielinska, Marzena ^{[1
]}

机构：

[1] Polish Acad Sci, Inst Human Genet, Strzeszynska 32, PL-60479 Poznan, Poland

[2] Poznan Univ Med Sci, Dept Gastroenterol, Dietet & Internal Dis, Przybyszewskiego 49, PL-60355 Poznan, Poland

来源：

TOXICS | 2022年 / 10卷 / 04期

关键词：

thiopurines; azathioprine; mercaptopurine; thioguanine; cytotoxicity; inflammatory bowel disease; Crohn's disease; ulcerative colitis; pharmacogenetics; therapeutic drug monitoring; AZATHIOPRINE METABOLITE CONCENTRATIONS; 6-THIOGUANINE NUCLEOTIDE LEVELS; EVIDENCE-BASED CONSENSUS; TERM-FOLLOW-UP; METHYLTRANSFERASE ACTIVITY; CROHNS-DISEASE; NUDT15; POLYMORPHISMS; COMBINATION THERAPY; MASS-SPECTROMETRY; CLINICAL-RESPONSE;

D O I：

10.3390/toxics10040151

中图分类号：

X [环境科学、安全科学];

学科分类号：

08 ; 0830 ;

摘要：

The effectiveness of thiopurine drugs in inflammatory bowel disease (IBD) was confirmed more than a half-century ago. It was proven that these can be essential immunomodulatory medications. Since then, they have been used routinely to maintain remission of Crohn's disease (CD) and ulcerative colitis (UC). The cytotoxic properties of thiopurines and the numerous adverse effects of the treatment are controversial. However, the research subject of their pharmacology, therapy monitoring, and the search for predictive markers are still very relevant. In this article, we provide an overview of the current knowledge and findings in the field of thiopurines in IBD, focusing on the aspect of their cytotoxicity. Due to thiopurines' benefits in IBD therapy, it is expected that they will still constitute an essential part of the CD and UC treatment algorithm. More studies are still required on the modulation of the action of thiopurines in combination therapy and their interaction with the gut microbiota.

引用

页数：19

共 112 条

[1] Update 2014: Advances to Optimize 6-Mercaptopurine and Azathioprine to Reduce Toxicity and Improve Efficacy in the Management of IBD [J].

Amin, Jaimin ;

Huang, Brian ;

Yoon, Jessica ;

Shih, David Q. .

INFLAMMATORY BOWEL DISEASES, 2015, 21 (02) :445-452

[2] Thiopurine pharmacogenomics and pregnancy in inflammatory bowel disease [J].

Andoh, Akira ;

Kawahara, Masahiro ;

Imai, Takayuki ;

Tatsumi, Goichi ;

Inatomi, Osamu ;

Kakuta, Yoichi .

JOURNAL OF GASTROENTEROLOGY, 2021, 56 (10) :881-890

[3] Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease [J].

Ansari, A. ;

Arenas, M. ;

Greenfield, S. M. ;

Morris, D. ;

Lindsay, J. ;

Gilshenan, K. ;

Smith, M. ;

Lewis, C. ;

Marinaki, A. ;

Duley, J. ;

Sanderson, J. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 28 (08) :973-983

[4] Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis [J].

Ardizzone, S ;

Maconi, G ;

Russo, A ;

Imbesi, V ;

Colombo, E ;

Porro, GB .

GUT, 2006, 55 (01) :47-53

[5] NUDT15 C415T variant compared with TPMT genotyping in predicting azathioprine-induced leucopenia: prospective analysis of 1014 inflammatory bowel disease patients in India [J].

Banerjee, Rupa ;

Ravikanth, Vishnubhotla Venkata ;

Pal, Partha ;

Bale, Govardhan ;

Avanthi, Urmila Steffie ;

Goren, Idan ;

Girish, B. Ganesh ;

Mitnala, Sasikala ;

Reddy, D. Nageshwar .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (11-12) :1683-1694

[6] Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease [J].

Bangma, Amber ;

Voskuil, Michiel D. ;

Uniken Venema, Werna T. C. ;

Brugge, Harm ;

Hu, Shixian ;

Lanting, Pauline ;

Franke, Lude ;

Dijkstra, Gerard ;

Festen, Eleonora A. M. ;

Weersma, Rinse K. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 51 (11) :1105-1115

[7] A comparative analysis of tioguanine versus low-dose thiopurines combined with allopurinol in inflammatory bowel disease patients [J].

Biemans, Vince B. C. ;

Savelkoul, Edo ;

Gabriels, Ruben Y. ;

Simsek, Melek ;

Dijkstra, Gerard ;

Pierik, Marieke J. ;

West, Rachel L. ;

de Boer, Nanne K. H. ;

Hoentjen, Frank .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 51 (11) :1076-1086

[8] Assessment of Thiopurine S-Methyltransferase Activity in Patients Prescribed Thiopurines: A Systematic Review [J].

Booth, Ronald A. ;

Ansari, Mohammed T. ;

Loit, Evelin ;

Tricco, Andrea C. ;

Weeks, Laura ;

Doucette, Steve ;

Skidmore, Becky ;

Sears, Margaret ;

Sy, Richmond ;

Karsh, Jacob .

ANNALS OF INTERNAL MEDICINE, 2011, 154 (12) :814-823

[9] Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease (Review) [J].

Boyapati, Ray K. ;

Torres, Joana ;

Palmela, Carolina ;

Parker, Claire E. ;

Silverberg, Orli M. ;

Upadhyaya, Sonam D. ;

Nguyen, Tran M. ;

Colombel, Jean-Frederic .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (05)

[10] Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis [J].

Brandse, Johannan F. ;

Mathot, Ron A. ;

van der Kleij, Desiree ;

Rispens, Theo ;

Ashruf, Yael ;

Jansen, Jeroen M. ;

Rietdijk, Svend ;

Lowenberg, Mark ;

Ponsioen, Cyriel Y. ;

Singh, Sharat ;

van den Brink, Gijs R. ;

D'Haens, Geert R. .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (02) :251-+

← 1 2 3 4 5 6 7 8 9 10 →